A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B

Parts 1, 2, and 3: Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability

Number of participants with AE (any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship) will be reported.

Time frame: Approximately up to 8 weeks

Parts 1, 2, and 3: Number of Participants With Clinically Significant Changes in Physical Examination (Body Weight Measurement and Skin Examination)

A symptom directed physical examination (including body weight measurement and skin examination) will be performed to further assess number of participants with clinically significant changes.

Time frame: Approximately up to 8 weeks

Parts 1, 2, and 3: Number of Participants With Clinically Significant Changes in Vital Signs

Number of participants with clinically significant changes in the vital signs will be reported.

Time frame: Approximately up to 8 weeks

Parts 1, 2, and 3: Number of Participants With ECG Abnormalities

Number of participants with electrocardiogram (ECG) abnormalities will be reported.

Time frame: Approximately up to 8 weeks

Parts 1, 2, and 3: Number of Participants With Holter Monitoring Abnormalities

Number of participants with Holter monitoring abnormalities will be reported.

Time frame: Up to 24 hours post-dose on Day 1

Parts 1, 2, and 3: Number of Participants With Clinical Laboratory Abnormalities

Number of participants with clinical laboratory abnormalities will be reported.

Time frame: Approximately up to 8 weeks

Part 1: Maximum Observed Plasma Concentration (Cmax)

The Cmax is the maximum observed plasma concentration.

Time frame: Day 1 (predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose)

Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last])

The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.

Time frame: Day 1 (predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose)

Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])

The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.

Time frame: Day 1 (predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose)

Part 3: Maximum Observed Plasma Concentration (Cmax)

The Cmax is the maximum observed plasma concentration.

Time frame: Day 1 (predose, and at 0.5, 1, 2, 4, 8, and 12 hours post dose), morning predose on Days 2, 15 and 21, and Day 28 (predose, and at 0.5, 1, 2, 4, 8, and 12 hours postdose; 24 hours postdose [once daily {QD} dosing only])

Part 3: Observed Plasma Concentration From Time 0 to tau Hours Postdose (C[0-tau])

C(0-tau) is defined as the observed plasma concentration from time 0 to tau hours postdose (tau = dosing interval).

Time frame: Day 1 (predose, and at 0.5, 1, 2, 4, 8, and 12 hours post dose), morning predose on Days 2, 15 and 21, and Day 28 (predose, and at 0.5, 1, 2, 4, 8, and 12 hours postdose; 24 hours postdose [QD dosing only])

Part 3: Area Under the Curve From Time Zero to End of Dosing Interval (AUC[0-tau])

The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption.

Time frame: Day 1 (predose, and at 0.5, 1, 2, 4, 8, and 12 hours post dose), morning predose on Days 2, 15 and 21, and Day 28 (predose, and at 0.5, 1, 2, 4, 8, and 12 hours postdose; 24 hours postdose [QD dosing only])